HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on Peptides & GLP-1. Browse all Peptides & GLP-1 education

Growth hormone response is not determined by a single gene. It’s the product of a multi-step cascade — from the pituitary pulse that initiates GH release to the liver’s conversion of that signal into IGF-1, to the fiber architecture and hypertrophy ceiling that determine what the signal builds, to the vascular and recovery systems that shape how effectively it arrives and how quickly it can be repeated. At least eight genes govern meaningful portions of that cascade. The Precision Peptide Genetic Test analyzes all of them as part of 15 Muscle Growth insights across 14 pathways, 49 peptides, and 150+ genetic insights.

The Genes That Trigger GH Release

GHSR — the growth hormone secretagogue receptor — is the primary genetic variable governing GH pulse amplitude from the pituitary. When ghrelin, a peptide hormone produced in the stomach, binds GHSR on pituitary somatotroph cells, it triggers a sharp GH release. GHSR has constitutive activity — it generates baseline GH signaling even without ligand — making receptor expression level a variable independent of ghrelin availability. Variants in GHSR influence both peak GH pulse amplitude and resting GH tone. Lower receptor sensitivity means smaller, less frequent pulses; higher sensitivity means a more robust GH axis output at the starting point of the entire cascade.

GHR — the growth hormone receptor — governs the second half of the trigger step. Once GH is released from the pituitary, it must bind GHR on hepatic cells to drive IGF-1 synthesis. GHR variants affect receptor expression level and binding efficiency. A strong GHSR-driven pulse that meets a poorly expressed GHR produces a weaker IGF-1 output than the same pulse meeting a highly expressed GHR. Both genes must be read together to understand the net GH signal reaching the liver.

The Genes That Convert GH Into Anabolic Action

IGF1 — the gene encoding insulin-like growth factor 1 — determines how efficiently the liver translates the GH signal from GHSR and GHR into circulating anabolic messenger. The 192bp CA microsatellite repeat polymorphism in the IGF1 promoter region is the most studied functional variant: 192bp allele carriers produce higher circulating IGF-1 in response to equivalent GH stimulation. Additional SNPs including rs35767 further influence IGF1 transcription rate. IGF-1 activates the PI3K/Akt/mTOR protein synthesis pathway and drives satellite cell proliferation — making it the direct molecular bridge between GH axis activity and actual muscle tissue growth.

This translation step is where inter-individual variation in muscle growth response is most frequently underestimated. Two people can have identical GH pulsatility from equivalent GHSR and GHR genotypes — and still produce meaningfully different quantities of circulating IGF-1 based on their IGF1 promoter genetics alone.

The Genes That Determine What the GH Signal Builds

ACTN3 (R577X) encodes alpha-actinin-3, a structural protein in fast-twitch muscle fibers. The R577X variant determines fast-twitch versus slow-twitch fiber composition. Since fast-twitch fibers hypertrophy more aggressively in response to IGF-1 signaling than slow-twitch fibers, ACTN3 genotype shapes how robustly the GH-driven anabolic signal expresses into visible mass. RR genotype individuals carry more fast-twitch fibers; XX genotype individuals carry more slow-twitch fibers and achieve hypertrophy through volume and frequency rather than single-session intensity.

MSTN (myostatin) is the primary biological brake on muscle mass accumulation. Regardless of how strong the GH→IGF-1 signal is, myostatin actively suppresses satellite cell proliferation and limits how much mass the body allows to accumulate. MSTN variants influence myostatin signaling activity — with the K153R variant (rs1805086) among the most studied, where the R allele is associated with reduced myostatin activity and a higher natural hypertrophy ceiling. MSTN genotype is the ceiling that GH axis signal strength can approach but not exceed.

The Supporting Genes: Amplification, Delivery, and Recovery

VDR (vitamin D receptor) amplifies GH axis anabolic signaling by upregulating IGF-1 receptor expression on muscle cell surfaces. More IGF-1 receptors means greater cellular sensitivity to the circulating IGF-1 that the GH axis generates. The FokI variant (rs2228570) is the most functionally significant: FF genotype produces a more transcriptionally active, shorter VDR protein that drives stronger downstream gene expression per unit of calcitriol. VDR genotype is effectively a gain dial on IGF-1 signaling sensitivity — independent of how much IGF-1 the GH axis produces.

ACE (angiotensin-converting enzyme) governs the vascular infrastructure through which IGF-1 physically reaches muscle tissue after the liver produces it. The I/D polymorphism determines ACE enzyme activity level: DD genotype carriers produce more angiotensin II, which directly stimulates muscle protein synthesis through AT1R alongside IGF-1; II genotype carriers produce more bradykinin, which promotes vasodilation and may enhance IGF-1 delivery efficiency. ACE adds or removes a secondary anabolic pathway operating independently of GH axis amplitude.

IL-6 (interleukin-6), as a myokine produced by contracting muscle, drives satellite cell activation through the JAK/STAT3 pathway — a parallel, exercise-triggered route to the same satellite cell proliferation that GH-axis IGF-1 drives through PI3K/Akt. The −174G/C variant (rs1800795) determines IL-6 production level per training session: GG genotype carriers produce a larger IL-6 myokine pulse with stronger satellite cell activation but higher per-session inflammatory load; CC carriers produce a more restrained pulse with faster recovery and better frequency tolerance. IL-6 genotype determines how much of the GH axis anabolic architecture can be productively activated per training week.

How the Precision Peptide Genetic Test Measures All of Them

The Precision Peptide Genetic Test analyzes all eight of these genes as part of 15 Muscle Growth insights — processed on the Illumina Global Screening Array at CLIA-certified labs, delivering results through the secure PlexusDx Results Portal. Each insight is paired with pathway context that situates the individual gene finding within the broader GH axis picture. Because no single gene determines GH response in isolation, results are most useful when read as a panel: GHSR and GHR together reveal the trigger sensitivity; IGF1 reveals translation efficiency; ACTN3 and MSTN reveal the reception architecture; VDR, ACE, and IL-6 reveal amplification, delivery, and recovery capacity.

For a systems-level explanation of how these eight genes interact as a cascade — including how compensating configurations work and what different genotype combinations mean in practice — see How Your Genetics Shape Growth Hormone Axis Peptide Response.

The Precision Peptide Genetic Test analyzes how your genes influence muscle growth pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to map your complete growth hormone response genetic profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About Genes and Growth Hormone Response

What genes affect growth hormone response?

Several genes shape GH response: GHSR (GH release trigger), GHR (growth hormone receptor), IGF1 (anabolic signal output), ACTN3 (fiber architecture), MSTN (hypertrophy ceiling), VDR (IGF-1 receptor amplification), ACE (vascular delivery), and IL-6 (recovery and satellite cell activation). The Precision Peptide Genetic Test analyzes all as part of 15 Muscle Growth insights.

How does genetic testing reveal growth hormone response?

Genetic testing identifies variants at every stage of GH axis function — from pulse generation (GHSR) to receptor sensitivity (GHR) to downstream IGF-1 output (IGF1) to what the signal builds (ACTN3, MSTN). The Precision Peptide Genetic Test delivers 15 Muscle Growth insights revealing your GH axis profile. Results guide healthcare conversations, not treatment decisions.

Can you test your growth hormone response genetically?

Yes — the Precision Peptide Genetic Test analyzes variants across the full GH response axis: GHSR, GHR, IGF1, ACTN3, MSTN, VDR, ACE, and IL-6, as part of 15 Muscle Growth insights. Analyzed on the Illumina Global Screening Array at CLIA-certified labs, results map your GH axis architecture without predicting response to any specific compound.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.